RxDoctor Payments Data

Bochen Tong, MD

Family Medicine · Richmond, TXNPI 1689092611

Payments from drug & device makers

$12,570in general payments, 2019–2025

Across 509 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Bayer$1K
  • Lilly USA, LLC$996
  • Abbott$925
  • plus $6K from 44 others

What the payments were for

  • Consulting fees$1,20010%
  • Travel & lodging$641%
  • Food & beverage$11,29790%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,570 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$115,020
Medicare patients
205
Services billed
2,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$57,990
OzempicSemaglutide27$38,578
EliquisApixaban44$34,224
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$33,825
MounjaroTirzepatide18$31,853
FarxigaDapagliflozin Propanediol12$19,553
JanuviaSitagliptin Phosphate13$18,676
Tresiba Flextouch U-200Insulin Degludec17$16,011
BrilintaTicagrelor12$13,791
VascepaIcosapent Ethyl13$13,132
LinzessLinaclotide14$9,858
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,903
Praluent PenAlirocumab13$6,608
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,459
TradjentaLinagliptin11$6,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$111$64,26461 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$838$42,83388 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$502$40,24835 claims
Novo NordiskOzempic$1,304$38,57827 claims
PfizerEliquis, Paxlovid$185$37,08267 claims
Lilly USA, LLCMounjaro$996$31,85318 claims
MerckJanuvia$321$18,67613 claims
AbbVieLinzess, Synthroid$1,281$11,74952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Richmond

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →